Sign Up to like & get
recommendations!
0
Published in 2021 at "Progress in Organic Coatings"
DOI: 10.1016/j.porgcoat.2021.106140
Abstract: Abstract Acrylic-alkyd copolymers with varied contents of the alkyd copolymer have been synthesized by free radical polymerization in order to create waterborne coatings with distinct molecular structures to enhance anti-corrosion performance. The acrylic-alkyd copolymers were…
read more here.
Keywords:
anti corrosion;
enhance anti;
corrosion;
corrosion performance ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Leukemia"
DOI: 10.1038/s41375-021-01301-6
Abstract: Immune profiling in patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma (MM) provides the framework for developing novel immunotherapeutic strategies. Here, we demonstrate decreased CD4+ Th cells, increased…
read more here.
Keywords:
myeloma;
multiple myeloma;
anti tumor;
lag3 gal ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2022.2139601
Abstract: ABSTRACT Introduction Oncolytic adenoviruses (Ads) are promising therapeutics to enhance anti-tumor immune responses and modulate the immune-suppressive tumor microenvironment (TME). Due to their potent ability to deliver genes in vivo, oncolytic Ads have been armed…
read more here.
Keywords:
anti tumor;
immune responses;
oncolytic adenoviruses;
tumor immune ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "Oncoimmunology"
DOI: 10.1080/2162402x.2023.2192100
Abstract: ABSTRACT Despite the recent emergence of immune checkpoint inhibitors, clinical outcomes of metastatic NSCLC patients remain poor, pointing out the unmet need to develop novel therapies to enhance the anti-tumor immune response in NSCLC. In…
read more here.
Keywords:
anti tumor;
combination;
therapy;
tumor immune ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2019.02083
Abstract: One major concern when treating patients with ICBs, such as anti-PD1 and anti-CTLA-4 antibodies, is the high frequency of immune-related adverse events. This, along with lacking a reliable biomarker for patient stratification, underscores the need…
read more here.
Keywords:
approaches enhance;
combinatorial approaches;
editorial combinatorial;
anti tumor ... See more keywords